Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.1487
- Book/Share 37.7947
- PB 9.3335
- Debt/Equity 0.5906
- CurrentRatio 0.784
- ROIC 0.3934
- MktCap 1567501674741.4292
- FreeCF/Share 13.9401
- PFCF 25.2868
- PE 14.1233
- Debt/Assets 0.2059
- DivYield 0.0303
- ROE 0.7786
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
News
Novo Nordisk Stock Eyes Worst Day Ever on Outlook Cut
Published: July 29, 2025 by: Schaeffers Research
Sentiment: Negative
Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's surprise cut to its full-year guidance due to a lower sales outlook for several drugs.
Read More
Ozempic maker stock just collapsed
Published: July 29, 2025 by: Finbold
Sentiment: Negative
Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), behind the weight-loss drug Wegovy and diabetes medication Ozempic, tumbled on Tuesday after the company slashed its full-year 2025 guidance, triggering a sharp sell-off from investors.
Read More
3 'Wide Moat' SWANs
Published: July 25, 2025 by: Seeking Alpha
Sentiment: Positive
Despite a greedy market, we've found three quality stocks - NVO, RGA, and CP - offering strong value, growth, and reliable dividends. Novo Nordisk leads obesity treatment with strong GLP-1 drugs, a robust pipeline, and a 3.1% yield, trading well below historical P/E. Reinsurance Group of America is an undervalued, financially sound dividend grower with global reach and double-digit earnings growth potential.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Read More
Novo Nordisk (NVO) is a Top-Ranked Momentum Stock: Should You Buy?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Novo Nordisk: Undervalued Despite Strong Growth Trend & Solid Market Share
Published: July 24, 2025 by: Seeking Alpha
Sentiment: Positive
I am bullish on Novo Nordisk due to its 62% global GLP-1 market share and dominant Ozempic sales, supporting long-term leadership. Novo Nordisk's diversified GLP-1 portfolio, including Rybelsus and pending pill versions, positions it well against competitors and broadens its addressable market. Consistent double-digit revenue and profit growth, plus strong Q2 2025 expectations, reflect robust demand and effective cost management.
Read More
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
Read More
Here's Why Novo Nordisk (NVO) is a Strong Value Stock
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Novo Nordisk: The Market Hasn't Given It Enough Respect
Published: July 23, 2025 by: Seeking Alpha
Sentiment: Negative
Healthcare stocks have lagged the S&P 500, with Novo Nordisk already hit hard by intense competition from Eli Lilly. Despite recent setbacks and a decelerating growth outlook, Novo Nordisk's valuation now reflects steep pessimism, suggesting the downside appears limited. Novo Nordisk's robust brand, R&D, and profit margins provide a significant moat, even as competition in the GLP-1 market intensifies.
Read More
Novo Nordisk's Moat Is Deeper Than You Think
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally. Obesity drug sales surged 65% YoY in Q1-FY25, driving total revenue growth of 18% and free cash flow of $1.38 billion. The company projects FY25 free cash flow between $8.14–$9.59 billion, supported by 48.43% EBIT margins and expanding manufacturing capacity.
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (July 2025)
Published: July 21, 2025 by: 24/7 Wall Street
Sentiment: Negative
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and almost $5 billion in the first quarter of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Fangzhou Inc., a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company.
Read More
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
Read More
3 Ridiculously Discounted Growth Stocks to Buy Now
Published: July 16, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points in This Article: Buying beaten-down stocks allows investors to purchase high-quality companies at bargain prices, capitalizing on market overreactions.
Read More
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
Read More
Novo Nordisk: The Market Doesn't Get It
Published: July 11, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk remains dominant in diabetes and obesity care, with strong growth and expanding market share despite recent investor concerns. The company's pipeline, especially the oral GLP-1 and Alzheimer's trial, offers significant long-term upside. The company needs to grow its top-line at mid-% to justify its current valuation. By assuming the market growth rate, the company is massively undervalued.
Read More
Smart Money Going in Senior Health: Key Stocks in Elderly Care
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Read More
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Published: July 09, 2025 by: CNBC
Sentiment: Positive
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval
Published: July 08, 2025 by: Reuters
Sentiment: Positive
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving 25% or more weight loss.
Read More
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Published: July 07, 2025 by: Benzinga
Sentiment: Negative
Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company's stock has plummeted approximately 18% over the past month, reflecting recent challenges.
Read More
Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Read More
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's fundamentals remain robust despite recent share price weakness, with strong sales and profit growth as well as a well-established pipeline. Concerns over CEO transition and compounding threats are overblown; FDA enforcement and strategic partnerships will redirect demand to branded Wegovy. An oral semaglutide approval later this year can help reignite share price momentum.
Read More
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Published: July 01, 2025 by: CNBC Television
Sentiment: Positive
Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.
Read More
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
6 International Stocks To buy in July
Published: June 27, 2025 by: 24/7 Wall Street
Sentiment: Positive
With over $5 trillion of new investment commitments to date, the U.S.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406